JCI - Citations to Unraveling the mechanism of action of thiazolidinediones

Citations to this article

Unraveling the mechanism of action of thiazolidinediones

C. Ronald Kahn, … , Lihong Chen, Shmuel E. Cohen

C. Ronald Kahn, … , Lihong Chen, Shmuel E. Cohen

Published December 1, 2000
Citation Information: J Clin Invest. 2000;106(11):1305-1307. https://doi.org/10.1172/JCI11705.

View: Text | PDF

Total citations by year

Year:	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2011	2010	2009	2006	2005	2004	2002	2001	1999	Total
Citations:	1	1	3	1	4	1	2	3	3	2	2	5	1	3	3	2	5	3	2	1	1	49

Citation information

Citations to this article (49)

Title and authors	Publication	Year
Adipose tissue macrophages secrete small extracellular vesicles that mediate rosiglitazone-induced insulin sensitization. Rohm TV, Castellani Gomes Dos Reis F, Isaac R, Murphy C, Cunha E Rocha K, Bandyopadhyay G, Gao H, Libster AM, Zapata RC, Lee YS, Ying W, Miciano C, Wang A, Olefsky JM	Nature metabolism	2024
Antidiabetic Drug Efficacy in Reduction of Mortality during the COVID-19 Pandemic Gonikman D, Kustovs D	Medicina	2023
Safety Assessment of Glucose-Lowering Drugs and Importance of Structured Education during Ramadan: A Systematic Review and Meta-Analysis. Shiju R, Akhil A, Thankachan S, Tuomilehto J, Al Arouj M, Bennakhi A	Journal of Diabetes Research	2022
Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes Gao S, Zhang Y, Liang K, Bi R, Du Y	Stem Cells International	2022
The Role of PPARs in Breast Cancer. Zhao B, Xin Z, Ren P, Wu H	Cells	2022
Global Epidemiology, Health Outcomes, and Treatment Options for Patients With Type 2 Diabetes and Kidney Failure Phillips J, Chen JH, Ooi E, Prunster J, Lim WH		2021
The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD) DM Tanase, EM Gosav, CF Costea, M Ciocoiu, CM Lacatusu, MA Maranduca, A Ouatu, M Floria	Journal of Diabetes Research	2020
Sclerostin‐Neutralizing Antibody Treatment Rescues Negative Effects of Rosiglitazone on Mouse Bone Parameters M Farrell, H Fairfield, S Costa, A D'Amico, C Falank, DJ Brooks, MR Reagan	Journal of Bone and Mineral Research	2020
Plasma Cathepsin D Activity Rather Than Levels Correlates With Metabolic Parameters of Type 2 Diabetes in Male Individuals L Ding, T Houben, Y Oligschlaeger, AV Bitorina, BJ Verwer, ME Tushuizen, R Shiri-Sverdlov	Frontiers in Endocrinology	2020
Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment? A Veelen, EE Tapia, J Oscarsson, P Schrauwen	Molecular Metabolism	2020
Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA) PR Rehani, H Iftikhar, M Nakajima, T Tanaka, Z Jabbar, RN Rehani	Journal of Diabetes Research	2019
Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment MJ Peláez-Jaramillo, AA Cárdenas-Mojica, PV Gaete, CO Mendivil	Diabetes Therapy	2018
Peroxisome proliferator–activated receptor γ (PPARγ) induces the gene expression of integrin α V β 5 to promote macrophage M2 polarization Q Yao, J Liu, Z Zhang, F Li, C Zhang, B Lai, L Xiao, N Wang	The Journal of biological chemistry	2018
Structural basis for specific ligation of the peroxisome proliferator-activated receptor δ CC Wu, TJ Baiga, M Downes, JJ la Clair, AR Atkins, SB Richard, W Fan, TA Stockley-Noel, ME Bowman, JP Noel, RM Evans	Proceedings of the National Academy of Sciences	2017
Parallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold KA Teske, G Rai, P Nandhikonda, PS Sidhu, B Feleke, A Simeonov, A Yasgar, A Jadhav, DJ Maloney, LA Arnold	ACS Combinatorial Science	2017
PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ L Han, WJ Shen, S Bittner, FB Kraemer, S Azhar	Future Cardiology	2017
Rosiglitazone influences adipose tissue distribution without deleterious impact on heart rate variability in coronary heart disease patients with type 2 diabetes A Grenier, P Brassard, OF Bertrand, JP Després, O Costerousse, N Alméras, P Poirier	Clinical Autonomic Research	2016
Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet JH Flory, JK Ukena, JS Floyd	Current Atherosclerosis Reports	2016
Pioglitazone therapy for HIV/HAART-associated lipodystrophy syndrome could increase subcutaneous fat mass in non-lipoatrophic but not in lipoatrophic regions S Okada, M Konishi, H Ishii	BMJ case reports	2016
Emerging treatments for post-transplantation diabetes mellitus T Jenssen, A Hartmann	Nature Reviews Nephrology	2015
The Role of Oxidized Cholesterol in Diabetes-Induced Lysosomal Dysfunction in the Brain C Sims-Robinson, A Bakeman, A Rosko, R Glasser, EL Feldman	Molecular Neurobiology	2015
Soy Protein Isolate Inhibits High Fat Diet-Induced Senescence Pathways in Osteoblasts to Maintain Bone Acquisition in Male Rats JR Chen, OP Lazarenko, ML Blackburn, TM Badger, MJ Ronis		2014
Higher omega-3 index is associated with increased insulin sensitivity and more favourable metabolic profile in middle-aged overweight men BB Albert, JG Derraik, CM Brennan, JB Biggs, GC Smith, ML Garg, D Cameron-Smith, PL Hofman, WS Cutfield	Scientific Reports	2014
Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases FA Monsalve, RD Pyarasani, F Delgado-Lopez, R Moore-Carrasco	Mediators of Inflammation	2013
Leptin and Adiponectin: Emerging Therapeutic Targets in Breast Cancer E Surmacz	Journal of Mammary Gland Biology and Neoplasia	2013
PPARγ agonist-induced alterations in Δ6-desaturase and stearoyl-CoA desaturase 1: Role of MEK/ERK1/2 pathway N Saliani, M Darabi, B Yousefi, B Baradaran, MS Khaniani, M Darabi, M Shaaker, A Mehdizadeh, T Naji, M Hashemi	World journal of hepatology	2013
Changing the Way We Think About Endothelial Cell Insulin Sensitivity, Nitric Oxide, and the Pathophysiology of Type 2 Diabetes: The FoxO Is Loose MT Kearney	Diabetes	2013
PPARγ Activation Inhibits Growth and Survival of Human Endometriotic Cells by Suppressing Estrogen Biosynthesis and PGE2 Signaling DI Lebovic, SK Kavoussi, JH Lee, SK Banu, JA Arosh	Endocrinology	2013
Optic atrophy 1 is an A-kinase anchoring protein on lipid droplets that mediates adrenergic control of lipolysis G Pidoux, O Witczak, E Jarnæss, L Myrvold, H Urlaub, AJ Stokka, T Küntziger, K Taskén	The EMBO Journal	2011
SIRT1 is regulated by a PPAR{γ}-SIRT1 negative feedback loop associated with senescence L Han, R Zhou, J Niu, MA McNutt, P Wang, T Tong	Nucleic Acids Research	2010
PPARG Regulates Gonadotropin-Releasing Hormone Signaling in LbetaT2 Cells In Vitro and Pituitary Gonadotroph Function In Vivo in Mice1 S Sharma, PM Sharma, DS Mistry, RJ Chang, JM Olefsky, PL Mellon, NJ Webster	Biology of reproduction	2010
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials SH Sheth, RJ Larson	BMC Infectious Diseases	2010
Pulmonary surfactant: an immunological perspective ZC Chroneos, Z Sever-Chroneos, VL Shepherd	Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology	2009
A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia DC Henderson, X Fan, B Sharma, PM Copeland, CP Borba, R Boxill, O Freudenreich, C Cather, AE Evins, DC Goff	Acta Psychiatrica Scandinavica	2009
PPARgamma2 Polymorphism and Human Health W He	PPAR Research	2009
Insulin Resistance and Improvements in Signal Transduction N Musi, LJ Goodyear	Endocrine	2006
Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS) P Froment, P Touraine	PPAR Research	2006
Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats Y Wu, JP Ouyang, K Wu, SS Wang, CY Wen, ZY Xia	British Journal of Pharmacology	2005
Insulinotropic and anti-inflammatory effects of rosiglitazone in experimental autoimmune diabetes WM Awara, AE el-Sisi, M el-Refaei, MM el-Naa, K el-Desoky	The review of diabetic studies : RDS	2005
Metabolic syndrome therapy: Prevention of vascular injury by antidiabetic agents LJ Dominguez, JR Sowers	Current Hypertension Reports	2005
The cyclopentenone prostaglandin 15-deoxyΔ12,14-prostaglandin J2 attenuates the development of zymosan-induced shock S Marzocco, RD Paola, E Mazzon, T Genovese, D Britti, A Pinto, G Autore, S Cuzzocrea	Intensive Care Medicine	2005
Potential Role of Oral Thiazolidinedione Therapy in Preserving ??-Cell Function in Type 2 Diabetes Mellitus: H Walter, G Lbben	Drugs	2005
Inactivation of Fatty Acid Transport Protein 1 Prevents Fat-Induced Insulin Resistance In Skeletal Muscle Jason K. Kim, Ruth E. Gimeno, Takamasa Higashimori, Hyo-Jeong Kim, Hyejeong Choi, Sandhya Punreddy, David J. Hirsch, Robin L. Mozell, Guo Tan, Alain Stricker-Krongrad, Jonathan J. Fillmore, Zhen-Xiang Liu, Jianying Dong, Gary Cline, Andreas Stahl, Harvey F. Lodish, Gerald I. Shulman	Journal of Clinical Investigation	2004
Effects of insulin-sensitising agents in mice with hepatic insulin resistance SE Cohen, YH Tseng, MD Michael, CR Kahn	Diabetologia	2004
Bone Is a Target for the Antidiabetic Compound Rosiglitazone SO Rzonca, LJ Suva, D Gaddy, DC Montague, B Lecka-Czernik	Endocrinology	2004
Rosiglitazone: A Review of its Use in the Management of Type 2 Diabetes Mellitus AJ Wagstaff, KL Goa	Drugs	2002
Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone Herbert L Bonkovsky, Riad Azar, Steven Bird, Gyongyi Szabo, Barbara Banner	Digestive Diseases and Sciences	2002
Both RXR antagonist and PPAR-gamma antagonist provide a novel therapeutic strategy for obesity and type 2 diabetes Toshimasa Yamauchi, Hironori Waki, Junji Kamon, Koji Murakami, Kiyoto Motojima, Kajuro Komeda, Hiroshi Miki, Naoto Kubota, Yasuo Terauchi, Atsuko Tsuchida, Nobuyo Tsuboyama-Kasaoka, Naoko Yamauchi, Tomohiro Ide, Wataru Hori, Shigeaki Kato, Masashi Fukayama, Yasuo Akanuma, Osamu Ezaki, Akiko Itai, Ryozo Nagai, Satoshi Kimura, Kazuyuki Tobe, Hiroyuki Kagechika, Koichi Shudo and Takashi Kadowaki	Journal of Clinical Investigation	2001
Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents JK Kim, JJ Fillmore, Y Chen, C Yu, IK Moore, M Pypaert, EP Lutz, Y Kako, W Velez-Carrasco, IJ Goldberg, JL Breslow, GI Shulman	Diabetes	1999

Advertisement